Recursion Pharmaceuticals, Inc.
RXRX
$3.05
-$0.10-3.18%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -81.79% | 586.72% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -81.79% | 586.72% | |||
| Cost of Revenue | -8.92% | -18.81% | |||
| Gross Profit | -25.76% | 42.81% | |||
| SG&A Expenses | -17.98% | 1.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.43% | -14.09% | |||
| Operating Income | -9.97% | 32.14% | |||
| Income Before Tax | -12.96% | 33.37% | |||
| Income Tax Expenses | -23,120.00% | 566.67% | |||
| Earnings from Continuing Operations | -8.68% | 33.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.68% | 33.36% | |||
| EBIT | -9.97% | 32.14% | |||
| EBITDA | -11.77% | 35.58% | |||
| EPS Basic | -8.13% | 43.44% | |||
| Normalized Basic EPS | -4.19% | 39.00% | |||
| EPS Diluted | -8.13% | 43.44% | |||
| Normalized Diluted EPS | -4.19% | 39.00% | |||
| Average Basic Shares Outstanding | 0.49% | 17.84% | |||
| Average Diluted Shares Outstanding | 0.49% | 17.84% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||